Why the study?
Does the use of nondepolarising neuromuscular blocking agents compromise cardiac performance in patients after dynamic cardiomyoplasty?
Does the use of nondepolarising neuromuscular blocking agents compromise cardiac performance in patients after dynamic cardiomyoplasty?
The use of nondepolarising neuromuscular blocking agents like rocuronium during noncardiac surgery appears safe and does not compromise cardiac performance in patients with prior dynamic cardiomyoplasty.
Answers are grounded in this paper and cite their sources.
Rocuronium may be hemodynamically safe post-cardiomyoplasty; single case leaves open need for prospective confirmation before practice change.
Dynamic cardiomyoplasty is a surgical treatment to improve cardiac performance in patients with end-stage heart failure by wrapping the latissimus dorsi muscle around the heart. The use of skeletal muscle raises concerns about the safety of neuromuscular blocking agents used during general anaesthesia in noncardiac surgery in patients after cardiomyoplasty. We describe the administration of rocuronium to a patient undergoing carotid endarterectomy 18 months after cardiomyoplasty. No clinically relevant effects on haemodynamics were observed. We conclude that the use of nondepolarising neuromuscular blocking agents for noncardiac surgery in patients after cardiomyoplasty does not compromise cardiac performance in a clinically relevant way, although the time between the cardiomyoplasty procedure and the use of nondepolarising neuromuscular blocking agents remains a concern.
No takes yet. Share an insight, caveat, or question.
Timmerman et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: